As PD-1 and PD-L1 are upregulated in septic patients, it is plausible that ICBs, which were developed as oncology drugs, can also be suitable for the treatment of sepsis, preventing the critical immunosuppression phase and overcoming its often-lethal consequences (16, 17). The gene discussed is PDCD1; the disease is Sepsis.